<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00842972</url>
  </required_header>
  <id_info>
    <org_study_id>3-2006-0005</org_study_id>
    <nct_id>NCT00842972</nct_id>
  </id_info>
  <brief_title>Is Carotid Intima-media Thickness Affected by A1C Variability?</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <brief_summary>
    <textblock>
      This study was conducted to evaluate the effect of A1C variability on the progression of
      carotid artery intima-media thickness in type 2 diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <condition>Type 2 Diabetes</condition>
  <condition>A1C Variability</condition>
  <eligibility>
    <study_pop>
      <textblock>
        typeII, Fluroscopy in carotid once a year during 2 years.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type II

          -  fluoroscopy in carotid once a year during 2 years

        Exclusion Criteria:

          -  type 1 diabetes

          -  history or clinical evidence of coronary artery disease or cerebral or peripheral
             vascular disease

          -  the presence of albuminuria (defined as 24 hour urine albumin excretion ≥ 30 mg)

          -  renal dysfunction (defined as creatinine blood level ≥ 2.0 mg/dL)

          -  hepatic dysfunction (defined as alanine aminotransferase and/or aspartate
             aminotransferase blood level ≥ 3 × upper normal limit)

          -  smoking within the past 3 months prior to commencement of the study

          -  use of any medication likely to alter IMT such as calcium channel blocker,
             thiazolidinedione, antiplatelet agent (clopidogrel, cilostazol)

          -  use of glucocorticoid

          -  pregnancy

          -  severe concomitant disease such as cancer

          -  infection

          -  Cushing's syndrome

          -  acromegaly, or any other disorder likely to alter glycemia

          -  primary hypercholesterolemia

          -  hypothyroidism or hyperthyroidism

          -  use of any hormonal drugs

          -  alcoholism or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>34 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2009</study_first_submitted>
  <study_first_submitted_qc>February 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2009</study_first_posted>
  <last_update_submitted>September 14, 2009</last_update_submitted>
  <last_update_submitted_qc>September 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ahn, Chul Woo</name_title>
    <organization>Gangnam Severance Hospital</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

